[Ocular toxicity of deferoxamine: description and analysis of three observations].
BACKGROUND
Deferoxamine is a specific chelating agent of trivalent anions: iron ion and aluminum ion. The main prescriptions for this treatment are primary non-curable by blood letting hemochromatosis, secondary hemosiderosis, and aluminum intoxication associated with chronic kidney failure. Since the early 1980s, ocular toxicity has been documented in several publications.


METHODS
We recorded three clinical observations of patients presenting symptoms of an ocular toxicity caused by deferoxamine. The prescription of this treatment related to the presence of secondary hemosiderosis (a case of primitive myelofibrosis and a case of chronic myelomonocytic leukemia treated by blood transfusion) and an aluminum intoxication affecting a patient with chronic kidney failure. All three patients presented a gradual loss of visual acuity. The following were predominantly observed at the fundus examination which showed pigmentary anomalies near the macula such as mottling and dispersion affecting the electrophysiological studies. The termination of the treatment did not result in an improvement in the symptomatology.


CONCLUSIONS
Considering the latest literature on the subject, the indications as well as the pharmaceutical properties of deferoxamine, the ophthalmological symptoms of this intoxication, the additional investigations and the anatomicopathological analyses are restated, together with the current pathogenical hypothesis.


CONCLUSIONS
Deferoxamine can cause ocular toxicity resulting in severe and permanent lesions of the retinal pigment epithelium. The occurrence of disorders of the fundus and visual acuity requires, before and during the treatment, regular ophthalmological monitoring combined with electrophysiological explorations. This allows early treatment of the hematological or kidney disorder.
Szwarcberg
J
J
Clinique Ophtalmologique, Hôpitaux Universitaires de Strasbourg, 1, place de l'hôpital, 67091 Strasbourg cedex. Ce texte a fait l'objet d'une présentation lors de la SFO 2001 (n 1102).
Mack
G
G
Flament
J
J
D000368:Aged; D003676:Deferoxamine / Q000009:adverse effects*; D005128:Eye Diseases / Q000139:chemically induced* / Q000175:diagnosis; D005260:Female; D006801:Humans; D007502:Iron Chelating Agents / Q000009:adverse effects
D007502:Iron Chelating Agents; D003676:Deferoxamine